Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
复制标题
DOI：
10.1016/s0140-6736(13)60995-2
复制
发表时间：
2013-08-03
期刊：
影响因子：
168.9
通讯作者：
Paldanius, Paeivi Maria
中科院分区：
文献类型：
--
作者：
Strain, W. David;Lukashevich, Valentina;Paldanius, Paeivi Maria
背景指南建议为老年2型糖尿病患者设定个体化血糖控制目标，尽管没有证据。我们的目的是评估在24周内设定和实现个体化目标的可行性，同时使用维格列汀与安慰剂降低常规HbA（1c）。方法在这项为期24周的多国双盲研究中，我们招募了未使用药物或控制不充分的(糖化血红蛋白A(1c) [HbA(1c)] >= 7.0%至
Background Guidelines suggest setting individualised targets for glycaemic control in elderly patients with type 2 diabetes, despite no evidence. We aimed to assess the feasibility of setting and achieving individualised targets over 24 weeks along with conventional HbA(1c) reduction using vildagliptin versus placebo.Methods In this multinational, double-blind, 24 week study, we enrolled drug-naive or inadequately controlled (glycosylated haemoglobin A(1c) [HbA(1c)] >= 7.0% to